Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (16858)	5/11/2004 10:43:13 PM
From: Bluegreen	Respond to of 17367

Hey CACAITO!!! So do you think Enbrel will keep Raptiva from ever bringing in more revenues that SG&A????? What odds do you place on Raptiva getting European approval??? Do you think both ING-1 and Neuprex are in the trash bin???? I would like to see the stock price at least in the 2 area by the end of the week.

To: Cacaito who wrote (16858)	5/20/2004 5:38:10 PM
From: Bluegreen	Respond to of 17367

Cacaito!!!!! Top THAT in your TOPCAT HAT!!!!!!! Was that YOU tossing your HAT in the air when they presented the FULL results in Budapest??????? Talk about pulling a RAPTIVA RABBIT OUT OF A HAT!!!!!>>>>>>>>The CLEAR study was randomized in a 2:1 ratio (Raptiva/placebo), with Raptiva patients being treated with a weekly 1mg/kg subcutaneous injection. The study was undertaken across Europe and in Canada, Australia, Israel and Mexico. Full results will be presented for the first time to the scientific community at the current EADV (European Academy of Dermatology and Venerology) Spring Congress in Budapest at 11.00am tomorrow, Saturday 1stMay.<<<<<<<<<<<